Drugs / MK-1966
last change Jan 2018 re-read 2 minutes ago

MK-1966

Developed for
neoplasm
Investigated by
Merck Sharp & Dohme LLC

Trials 1 · a red edge is where a trial was stopped

2017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02731742 Jun 2016 → Jan 2018 neoplasm Merck Sharp & Dohme LLC Terminated No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MK-1966 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02731742
Route Intravenous “administered as an intravenous (IV) infusion” NCT02731742